| No. | Median follow-up | Males % | Age yrs | Exposure (smoking status) | Ratio of COPD | Positive screening for nodules | Lung cancer | Stage I | Lung cancer operability | Mortality | Lung cancer mortality |
| 1 | NR | 90 | 60.4 (38–83) | NR | NR | 20.30% | 15 (0.3%) | 14 (93%) | 14 (93%) | NR | NR |
| 2 | NR | 54 | 67 | Current 100% | NR | 0.23 | 33 (3.3%) | 28 (84.8%) | NR | NR | NR |
| 3 | NR | 46 | 65 | Current 54.3% | NR | 5.1% (1996) | 60 (0.4%) | 55 (92%) | 60 (100%) | 5 (0.1%) | 2 (0.04%) |
| 4.0% (1997) | |||||||||||
| 3.5% (1998) | |||||||||||
| 4 | NR | 98 | 63 (38–81) | Current 97% | NR | 18.4% | 5 (0.8%) | 2 (40%) | 1 (20%) | NR | 4 (0.7%) |
| 5 | NR | 88 | 64 | Current 61% | NR | 11.5% (initial) | 14 (0.9% initial) | 11 (78.6% initial) | 12 (86% initial) | 8 (0.5%) | 3 (0.2%) |
| Former 25% | 9.1% (repeated) | 22 (0.3% repeated) | 18 (82% repeated) | 17 (77% repeated) | |||||||
| 6 | NR | 72 | 53 (40–78) | Current 100% | NR | 43% | 11 (1.3%) | 7/12 lesions (58%) | 7/12 lesions (58%) | 4 (0.5%) | 2 (0.2%) |
| 7 | NR | 79 | NR | Current 62.1% | NR | 26.4% (initial) | 40 (0.5%) | 35 (87.5%) | 40 (100%) | NR | NR |
| 8 | NR | 71 | 58 (50–84) | Current 86% | NR | 29% | 22 (2.1%) | 17 (77%) | 21 (95%) | 8 (0.8%) | 1 (0.1%) |
| 9 | 5 yrs | 52 | 59 (50–85) | Current 61% | NR | 51% (initial), 74% (total) | 66 (4.3%) | 17/28 subsequent NSCLC cases (61%) | NR | 48 (3.2%) | 9 (0.6%) |
| 10 | NR | 59 | NR | Current 58% | NR | 34.5% | 40 (2.4%) | 19 (48%) | NR | NR | NR |
| NR | 15.8% | 20 (1.2%) | 8 (40%) | NR | NR | NR | |||||
| 11 | NR | 71 | 56 (47–75) | Current 65.0% | NR | 45.2% | 8 (2.1%) | 3 (37.5%) | NR | NR | NR |
| 56 (47–76) | Current 64.0% | NR | 7.4% | 1 (0.8%) | 1 (100%) | ||||||
| 12 | 33.7 (1.8–79.2) months | 100 | 64.3 | Current 56.0% | 446 (35%)# | 27.5% | 60 (4.7%) | 33 (55%) | 39 (65%) | 46 (3.6%) | 20 (1.6%) |
| 64.6 | Current 56.9% | 370 (30.1%)# | 8.9% | 34 (2.8%) | 12 (35%) | 17 (50%) | 45 (3.8%) | 20 (1.7%) | |||
| p=0.04 | p=0.016 | p=0.004 | p=0.25 | p=0.83 | p=0.84 | ||||||
| 13 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| 14 | NR | 59 | 61.4 | Current 48% | 4674 (17.5%) | NR | NR | NR | NR | NR | 354 (1.3%) |
| 4652 (17.4%) | 442 (1.7%) | ||||||||||
| 15 | 40 (1–123) months | NR | 61 (40–85) | Current or former 82.8% | NR | NR | 484 | 412 (85%) | 411 (85%) | NR | 75 |
Follow-up period data are provided with ranges where possible. Age data are presented as mean or median and range. COPD: chronic obstructive pulmonary disease; NR: not reported; NSCLC: nonsmall-cell lung cancer. #: chronic respiratory symptoms (DANTE trial).